Targeting this largely MM-specific molecule with CD3/GPRC5D bispecific antibodies and CAR T-cells in preclinical settings has already shown promising results and ongoing clinical studies will expose its suitability as a MM-target (27, 29). The gene discussed is GPRC5D; the disease is Miyoshi myopathy.